

## Afghanistan

### Support for Vaccine: Rotavirus This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Afghanistan						
<b>2. Vaccine grant number:</b>	18-AFG-08b-Y, 1819-AFG-13b-X, 20-AFG-13b-X						
<b>3. Date of Decision Letter:</b>	30-Sep-19						
<b>4. Date of the Partnership Framework Agreement:</b>	30-Apr-13						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Rotavirus, Routine						
<b>6. Vaccine type:</b>	Rotavirus						
<b>7. Requested product presentation and formulation of vaccine:</b>	RV1, 1 dose/plastic tube, liq						
<b>8. Programme Duration:<sup>1</sup></b>	2018-2020						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2018-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	10,594,500	6,272,000	-	-	-	-	16,866,500
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2018	18-AFG-08b-Y					977,902
	<b>Disbursement</b>						
	<b>Disbursement date</b>						<b>Amount (US\$)</b>
	18 January, 2018						356,452
	29 January, 2018						621,450
<b>11. Product switch grant</b>	<b>Not applicable</b>						

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

<b>12. Indicative Annual Amounts:<sup>3</sup></b>		(subject to the terms of the Partnership Framework Agreement, if applicable)			
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2018-2019</b>	<b>2020</b>	<b>2021</b>		
Number of vaccine doses		2,673,500	-		
Annual Amounts (US\$)	10,594,500	6,272,000	-		
<b>13. Procurement agency:</b>		UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>14. Self-procurement:</b>		Not applicable			
<b>15. Co-financing obligations:</b>		According to the co-financing policy, the Country falls within the group: Initial self-financing			
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>	<b>2024</b>
Number of vaccine doses	250,500	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	571,050	-	-	-	-
Total co-financing payments (US\$) (including freight)	585,000	-	-	-	-
<b>16. Operational support for campaigns:</b>		Not applicable			

**17. Additional Reporting Requirements:**

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2020 15 May 2020</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

**18. Financial clarifications:** Country shall provide the following clarifications to Gavi\*:

Not applicable

\* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

**19. Other conditions:**

Not applicable

**On behalf of Gavi**



Thabani Maphosa  
Managing Director, Country Programmes  
30 September 2019